SCHEMBL176228

SCHEMBL176228

C=CCOC(=O)CC[C@H](N)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 3/20 0.48
GRIK2 Q13002 3/20 0.48
SLC1A1 P43005 2/20 0.48
GSR P00390 2/20 0.48
GRM8 O00222 1/20 0.48
GRM6 O15303 1/20 0.48
GRIN2D O15399 1/20 0.48
GRIN3B O60391 1/20 0.48
CYP1A2 P05177 1/20 0.48
GRM5 P41594 1/20 0.48
GRIA1 P42261 1/20 0.48
GRIA2 P42262 1/20 0.48
GRIA3 P42263 1/20 0.48
SLC1A3 P43003 1/20 0.48
SLC1A2 P43004 1/20 0.48
GRIA4 P48058 1/20 0.48
GRIN1 Q05586 1/20 0.48
GRIN2A Q12879 1/20 0.48
GRIK3 Q13003 1/20 0.48
GRIN2B Q13224 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL666790 1.00 GRIK1 (0.48) GRIK1GRIK2SLC1A1GSRGRM8
Trifluoroacetic Acid SCHEMBL30280654 0.91 GRIK1 (0.41) GRIK1GRIK2SLC1A1GSRGRM8
Trifluoroacetic Acid SCHEMBL28528219 0.89 GRIK1 (0.40) GRIK1GRIK2SLC1A1GSRGRM8
SCHEMBL176227 0.87 TSHR (0.47) GRIK1GRIK2SLC1A1GSRGRM8
SCHEMBL3968417 0.87 TSHR (0.47) GRIK1GRIK2SLC1A1GSRGRM8
SCHEMBL176229 0.87 TSHR (0.47) GRIK1GRIK2SLC1A1GSRGRM8
SCHEMBL31714254 0.87 GRIK1 (0.43) GRIK1GRIK2SLC1A1GSRGRM8
SCHEMBL6422885 0.86 TSHR (0.46) GRIK1GRIK2SLC1A1GSRGRM8
SCHEMBL5141195 0.86 TSHR (0.46) GRIK1GRIK2SLC1A1GSRGRM8
SCHEMBL28276401 0.83 TSHR (0.50) BLMKMT2ATSHRTDP1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 782 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250208137-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES CAMBRIDGE ENTERPRISE LIMITED (GB) 2025-06-26 US claimed
EP-4493273-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES Politechnika Wroclawska (PL) 2025-01-22 EP claimed
WO-2024073333-A1 HARD SURFACE CLEANING COMPOSITIONS COMPRISING RHAMNOLIPIDS AND GLUTAMATE CO-SURFACTANT STEPAN COMPANY (US) 2024-04-04 WO claimed
WO-2024002698-A1 COSMETIC COMPOSITION OF LIQUID CRYSTAL LIPID PARTICLES FOR IMPROVED ANTIOXIDANT EFFECTS BASF SE (DE) 2024-01-04 WO claimed
WO-2023175356-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES POLITECHNIKA WROCLAWSKA (PL) 2023-09-21 WO claimed
WO-2023053960-A1 SKIN EXTERNAL AGENT CONTAINING 12-HYDROXYSTEARIC ACID AND HAVING α-GEL STRUCTURE 株式会社 資生堂 2023-04-06 WO claimed
EP-3621578-B1 LOW VISCOSITY, HIGH POLYOL SELF-FOAMING COMPOSITION UNILEVER IP HOLDINGS B V (NL) 2022-02-16 EP claimed
EP-3902899-A1 HOME CARE COMPOSITIONS Colgate-Palmolive Company (US) 2021-11-03 EP claimed
CN-113227339-A Home care compositions 高露洁-棕榄公司 2021-08-06 CN claimed
US-10975332-B2 Home care compositions COLGATE-PALMOLIVE COMPANY (US) 2021-04-13 US claimed
US-5840671-A TERTIARY AMINE OXIDE TOMEY TECHNOLOGY CORPORATION (JP) 1998-11-24 US claimed
EP-0717101-A1 Cleaning solution for contact lens TOMEY TECHNOLOGY CORPORATION (JP) 1996-06-19 EP claimed
EP-0527851-A1 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1993-02-24 EP claimed
WO-1991017148-A1 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1991-11-14 WO claimed
US-4976962-A Biodegradable polypeptide and the use thereof for the gradual release of drugs BRACCO RESEARCH S.A. (CH) 1990-12-11 US claimed
US-4892733-A DRUG DELIVERY, HOMO-AND CO-POLYMERS OF ASPARTIC AND GLUTAMIC ACID IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-01-09 US claimed
US-4888398-A ALKYL- OR ACRYLOXYCARBONYLMETHYL POLYASPARTATE AND POLYGLUTAMATE BATTELLE MEMORIAL INSTITUTE (CH) 1989-12-19 US claimed
EP-0213996-B1 RAMIFIED POLYMERS BASED ON LIPOPEPTIDES FORMING THERMOTROPIC AND LYOTROPIC LIQUID CRYSTALS, THEIR USE AND CORRESPONDING MONOMERS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1989-09-06 EP claimed
US-4675381-A Biodegradable polypeptide and its use for the gradual release of drugs BATTELLE MEMORIAL INSTITUTE (CH) 1987-06-23 US claimed
EP-0130935-B1 BIODEGRADABLE POLYPEPTIDE AND ITS USE IN THE SUSTAINED RELEASE OF MEDICAMENTS BATTELLE MEMORIAL INSTITUTE (CH) 1987-04-15 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250208137-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES F11, F2, F12 GRIK1 4184/4885GRIK2 4711/4885SLC1A1 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.